Effect Of Pirfenidone On All-Cause Mortality (acm) And Forced Vital Capacity (FVC) In Idiopathic Pulmonary Fibrosis (ipf) Patients With Low FVC And/or Low Dlco: Analysis Of Pooled Data From Ascend And Capacity

被引：0
|
作者：
Nathan, S. D. [1 ]
Costabel, U. [2 ]
Albera, C. [3 ]
Kirchgassler, K. -U. [4 ]
Chou, W. [5 ]
Noble, P. W. [6 ]
机构：
[1] Inova Fairfax Hosp, Falls Church, VA USA
[2] Univ Duisburg Essen, Ruhrlandklin, Essen, Germany
[3] Univ Turin, Turin, Italy
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5390
引用
收藏
页数：1
相关论文
共 34 条
  • [1] EFFECT OF PIRFENIDONE ON ALL-CAUSE MORTALITY (ACM) AND FORCED VITAL CAPACITY (FVC) IN IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENTS WITH LOW FVC AND/OR LOW DLCO: ANALYSIS OF POOLED DATA FROM ASCEND AND CAPACITY
    Nathan, S. D.
    Costabel, U.
    Albera, C.
    Kirchgaessler, K. U.
    Chou, W.
    Noble, P. W.
    THORAX, 2017, 72 : A254 - A254
  • [2] Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY
    Nathan, Steven D.
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    du Bois, Roland M.
    Fagan, Elizabeth A.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Kardatzke, David
    King, Talmadge E., Jr.
    Kirchgaessler, Klaus-Uwe
    Lancaster, Lisa H.
    Lederer, David J.
    Pereira, Carlos A.
    Swigris, Jeffrey J.
    Valeyre, Dominique
    Noble, Paul W.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [3] Effect of Pirfenidone on All-Cause Mortality in Patients With Idiopathic Pulmonary Fibrosis (IPF): Comparison of Pooled Analysis With Meta-analysis From the ASCEND and CAPACITY Trials
    Nathan, Steven
    Albera, Carlo
    Bradford, Williamson
    Costabel, Ulrich
    Daigl, Monica
    Kirchgaessler, Klaus-Uwe
    Du Bois, Roland
    Glaspole, Ian
    Glassberg, Marilyn
    King, Talmadge
    Lancaster, Lisa
    Lederer, David
    Pereira, Carlos
    Swigris, Jeffrey
    Valeyre, Dominique
    Noble, Paul
    CHEST, 2015, 148 (04)
  • [4] Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) - modelling the myth
    Wijsenbeek, Marlies
    Santermans, Eva
    Ford, Paul
    Kreuter, Michael
    Verbruggen, Nadia
    Meyvisch, Paul
    Wuyts, Wim
    Brown, Kevin
    Lederer, David
    Maher, Toby
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [5] Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
    Costabel, Ulrich
    Albera, Carlo
    Kirchgaessler, Klaus-Uwe
    Gilberg, Frank
    Petzinger, Ute
    Noble, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [6] Effect of Pirfenidone on IPF-Related Mortality Outcome Measures in Patients With Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis From the ASCEND and CAPACITY Trials
    Nathan, Steven
    Albera, Carlo
    Bradford, Williamson
    Kardatzke, David
    Costabel, Ulrich
    du Bois, Roland
    Glaspole, Ian
    Glassberg, Marilyn
    King, Talmadge
    Kirchgaessler, Klaus-Uwe
    Lancaster, Lisa
    Lederer, David
    Pereira, Carlos
    Swigris, Jeffrey
    Valeyre, Dominique
    Noble, Paul
    CHEST, 2015, 148 (04)
  • [7] Improvement In Forced Vital Capacity (FVC) With Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf): Results From The Inpulsis Trials
    Flaherty, K. R.
    Kolb, M.
    Vancheri, C.
    Tang, W.
    Conoscenti, C. S.
    Richeldi, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] EFFECT OF CONTINUED TREATMENT WITH PIRFENIDONE FOLLOWING A ≥ 10% RELATIVE DECLINE IN PERCENT PREDICTED FORCED VITAL CAPACITY (%FVC) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Wells, A. U.
    Albera, C.
    Costabel, U.
    Glaspole, I.
    Glassberg, M. K.
    Lancaster, L.
    Lederer, D. J.
    Pereira, C. A.
    Swigris, J. J.
    Day, B-M
    Chou, W.
    Nathan, S. D.
    THORAX, 2016, 71 : A178 - A178
  • [9] Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons
    Nathan, Steven D.
    Wanger, Jack
    Zibrak, Joseph D.
    Wencel, Mark L.
    Burg, Cindy
    Stauffer, John L.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (02) : 175 - 181
  • [10] Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
    Lasseniusa, Mariann I.
    Toppila, Iiro
    Pontynen, Nora
    Kasslin, Laura
    Kaunisto, Jaana
    Kilpelainen, Maritta
    Laitinen, Tarja
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2020, 7 (01):
1234